Repligen (RGEN) Earnings Analysis
Repligen (RGEN) has no confirmed upcoming earnings date. Last quarter (2025-02-20) it beat with EPS 0.44 USD vs 0.41 USD est (+7.3%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 153.95.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does RGEN next report earnings?
No confirmed upcoming earnings date is currently scheduled for RGEN. This page updates as the calendar is published.
RGEN earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-02-20 | 0.44 USD | 0.41 USD | +7.3% | Beat |
| 2024-07-29 | 0.33 USD | 0.33 USD | 0% | Beat |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
RGEN valuation and analyst view
| Trailing P/E | 153.95 |
|---|---|
| Trailing EPS | 0.91204 USD |
| Price / book | 3.75 |
| Dividend yield | 0.00% |
| Market cap | 7.96B |
| Analyst consensus | Buy (22 buy / 2 hold / 0 sell) |
| Avg price target | 154 USD |
Related research pages
Frequently asked questions
When is Repligen (RGEN)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for RGEN. This page updates as the calendar is published.
Did RGEN beat earnings last quarter?
In its 2025-02-20 report, RGEN posted EPS of 0.44 USD versus a 0.41 USD estimate — a beat of 7.3%.
What is RGEN's earnings track record?
Over the last 2 reported quarters with consensus data, RGEN beat estimates 2 times (100%).
What is RGEN's current P/E ratio and EPS?
RGEN trades at a trailing P/E of 153.95 on trailing EPS of 0.9120381871739361 USD.
What do analysts rate RGEN?
Analyst consensus is "Buy" across 24 ratings (1 strong buy, 21 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 154 USD.